About Hedera Dx
Hedera Dx provides a liquid biopsy solution that streamlines tumor profiling and cancer treatment monitoring for patients, enabling hospital laboratories to perform CE-IVDR compliant and clinically actionable liquid biopsies in-house.
Mission and Vision
Hedera Dx is united by a vision to make liquid biopsies globally accessible to patients. It aims to expand treatment options without the usual hurdles, improving pathways to personalized cancer therapy.
Key Features and Solutions
The company offers a registered CE-IVD medical device software called Hedera Prime combined with a targeted pan-cancer assay, Hedera Profiling 2 ctDNA, designed to integrate easily into molecular pathology laboratories. They support clinical validation studies like the EMPATHY NSCLC to provide real-world utility data and encourage decentralized in-house testing.
Clinical Impact
Hedera Dx's solution addresses high R&D, compliance challenges, and inefficiencies in current workflows, providing physicians with regulatory-approved therapy options based on ctDNA sequencing from blood samples.
Contact and Socials
Address: Route de la Corniche 5, 1066 Epalinges, Switzerland
Phone: +41 21 588 16 54
LinkedIn: https://www.linkedin.com/company/hedera-dx/